AKTS

Aktis Oncology, Inc.

Healthcare · Biotechnology

$107.56 sample

-1.01 (-0.93%) 1D

Market cap

$579.8B

Price as of

2026-10-24

Latest filing

8-K · 2026-10-19

Alerts

8

Price$107.56 +8.97% 3M daily closessample

108.7898.71

2026-07-282026-08-192026-09-102026-10-012026-10-23

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 19SECDEF 14A filed
Oct 14SEC8-K filed: material event
Oct 05INSInsider buy: EVP, Operations
Sep 25INSInsider sell: EVP, Operations
Sep 21INSInsider sell: Chief Financial Officer
Sep 10INSInsider buy: EVP, Operations
Sep 04INSInsider sell: Chief Financial Officer
Aug 31INSInsider sell: EVP, Operations

Sign up to see the real AKTS record →

Company facts

SEC EDGAR registration

Name: Aktis Oncology, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -57sample, -100 to +100
Reporting currency: USD

Who is positioning in AKTS

sample

Insiders: 33 insider transactions over 90 days, net selling, $490.4M
Congress: 1 members traded over 90 days
Institutions · 13F: 38 funds hold $7.7B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$17.6B +17.7% y/y

Q4 2024Q3 2026

Inventory$10.6B +4.9% y/y

Q4 2024Q3 2026

Accounts receivable$8.2B +18.1% y/y

Q4 2024Q3 2026

Total debt$22.3B +21.0% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $222.2B -9.8% 3M
Sample peer B: $528.9B +15.7% 3M
Sample peer C: $463.5B -10.3% 3M
Sample peer D: $438.5B -11.0% 3M
Sample peer E: $538.3B +16.1% 3M